Showing 3581-3590 of 5559 results for "".
- Kenneth J. Tomecki, MD, FAAD is New President of the AADhttps://practicaldermatology.com/news/kenneth-j-tomecki-md-faad-is-new-president-of-the-aad/2460723/Kenneth J. Tomecki, MD, FAAD is now president of the American Academy of Dermatology (AAD). During his one-year term, Dr. Tomecki will lead the world’s largest dermatologic society, representing more than 20,000 physicians specializing
- Vyne Therapeutics to Move Forward with Topical Tofacitinib/Fingolimod Gel for ADhttps://practicaldermatology.com/news/vyne-therapeutics-to-move-forward-with-topical-tofacitinibfingolimod-gel-for-ad/2460707/Vyne Therapeutics Inc. plans to move forward on development of its fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical gel for mild-to-moderate atopic dermatitis. A phase 2a proof of concept study for FMX114 is planned to start
- Merz Rolls Out Belotero Balance(+) with Lidocaine in the UShttps://practicaldermatology.com/news/merz-rolls-out-belotero-balance-with-lidocaine-in-the-us/2460675/Merz Aesthetics is launching Belotero Balance(+) with Lidocaine in the US. “Healthcare providers can now rely on the well-known rheological properties and performance of Belotero Balance with the time savings and consistency of a pre-mixed lidocaine formulation,” says Patric
- Study: Acute Itching in AD Linked to Environmental Triggershttps://practicaldermatology.com/news/study-acute-itching-in-ad-linked-to-environmental-triggers/2460658/Allergens in the environment often are to blame for episodes of acute itch in eczema patients, and that this itching often doesn’t respond to antihistamines because the itch signals are being carried to the brain along a previously unrecognized pathway that current drugs don’t ta
- Novartis: Ligelizumab Receives Breakthrough Therapy Designation in CSUhttps://practicaldermatology.com/news/novartis-ligelizumab-receives-breakthrough-therapy-designation-in-csu/2460656/Ligelizumab from Novartis now has Breakthrough Therapy designation from FDA for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. Ligelizumab
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- Study: Iron Oxides Offer Protection Skin from Blue Lighthttps://practicaldermatology.com/news/study-iron-oxides-protection-skin-from-blue-light/2460616/Iron oxides provide enhanced protection against HEV or blue light, especially when combined with zinc oxide, according to results of a new study in The Journal of Cosmetic Dermatology. HEV
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former